U.S. markets closed

Dassault Systèmes SE (DSY.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
153.35+0.55 (+0.36%)
At close: 5:35PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close152.80
Bid0.00 x 0
Ask0.00 x 0
Day's Range152.80 - 154.20
52 Week Range105.00 - 164.15
Avg. Volume277,137
Market Cap39.989B
Beta (5Y Monthly)0.65
PE Ratio (TTM)86.49
Earnings DateN/A
Forward Dividend & Yield0.70 (0.47%)
Ex-Dividend DateMay 28, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      German defence supplier Hensoldt files for Frankfurt stock market listing

      German defence supplier Hensoldt has filed for a Frankfurt stock market listing later this month, as the private equity-owned company seeks to raise funds for growth and to strengthen its balance sheet. The deal is expected to value the former Airbus unit, which buyout group KKR bought in 2016, at 2.5-3 billion euros ($3-3.5 billion), including debt, people close to the matter said.

    • Dassault Systemes SE (DASTY) Q2 2020 Earnings Call Transcript
      Motley Fool

      Dassault Systemes SE (DASTY) Q2 2020 Earnings Call Transcript

      Ladies and gentlemen and thank you for standing by, and welcome to the Dassault Systemes Q2 and H1 2020 Earnings Call. Thank you for joining us on our second quarter earnings conference call, with Bernard Charles, Vice Chairman and CEO; and Pascal Daloz, Chief Operating Officer and Chief Financial Officer. Dassault Systemes' results are prepared in accordance with IFRS.

    • Reuters

      Pharmas restart drug trials after pandemic-related declines, Medidata finds

      The research, which was prepared by clinical trial technology company Medidata, shows that the number of new subjects entering trials increased 112% in June compared with the low point in April. Drugmakers around the world, including Eli Lilly & Co and Galapagos NV have announced plans to delay clinical trials for some drugs because of difficulties recruiting, treating and monitoring patients during the pandemic. In response, regulators, including the U.S. Food and Drug administration, have eased rules around collecting data remotely using digital tools to try to help drugmakers continue to research new treatments.